Current status byetta pharmaceutical company 2026?

Do you mean the company that currently markets Byetta (exenatide) as of 2026, or the corporate history behind it? I can give both, just want to be sure.

Here’s the quick answer:

- Current marketer: Byetta is marketed by Eli Lilly and Company (Lilly). The drug is a GLP-1 receptor agonist for type 2 diabetes.
- Original development/ownership: Byetta was originally developed by Amylin Pharmaceuticals. Amylin was acquired by Bristol-Myers Squibb in 2012, and Lilly later acquired Amylin’s diabetes assets (including exenatide products). Byetta remains an Lilly product.
- Related product: Lilly also markets Byetta’s extended-release counterpart, Bydureon (exenatide extended-release).

If you want, I can look up more detailed, region-specific status (e.g., US vs. EU), regulatory notes, or recent corporate filings.